The U.S. Food and Drug Administration (FDA) announced that it is assessing the risk of brain deposits from the use of gadolinium-based contrast agents during magnetic resonance imaging (MRI). According to the agency, there have been reports of deposits of the contrast agent remaining in the brains of some patients who have four or more contrast MRI scans.

The FDA notes that it will study the potential adverse health effects but will not require any label changes from manufacturers of gadolinium-based contrast agents at this time.

Read the FDA announcement.

Keywords: Brain, Contrast Media, Gadolinium, Magnetic Resonance Imaging, United States Food and Drug Administration

< Back to Listings